We aim to translate these findings into patients with rheumatoid arthritis and other
conditions treated with anti-TNF (anti-tumor necrosis factor) therapy, such as psoriatic
arthritis and ankylosing spondylitis. Patients from rheumatology clinics within NHS (National
Health Service) trusts will be recruited. We will correlate disease activity assessed by
clinical parameters, ultrasonography, and questionnaires with biomarkers in the blood and
target tissues, such as synovium and skin.